Fig. 6
From: p90RSK pathway inhibition synergizes with cisplatin in TMEM16A overexpressing head and neck cancer
Cisplatin and BI-D1870 combine to reduce tumor growth in TMEM16A expressing HN30 cells in vivo. (A) Tumor volumes (mm3) in mice xenografted with HN30 cells after treatment with cisplatin and BI-D1870. Statistical significance for A was calculated using repeated measures two-way ANOVA with Tukey’s multiple comparison test. *p < 0.05, ***p < 0.0001. (B) Images of harvested tumors after treatment completion on Day 12. (C) Dot plot of the weights of harvested tumors (g) after treatment completion. Statistical significance was calculated using one-way ANOVA with Tukey’s multiple comparison test. *p < 0.05, ***p < 0.0001. (D-E) pH2AX staining and analysis in harvested tumors from each treatment group. Images were taken at 40X. Statistical significance was calculated using Fisher’s exact test. *p < 0.05, ***p < 0.0001